Avid Bioservices Inc (CDMO)

[entdoc]

jakedog, my take is that the ECOG status is CRITICALLY important in a small trial, and the differences you point out are probably important. I am not one bit deterred by these results, and anyone who is simply does not have the experience to understand what a nightmare we are dealing with in metastatic pancreatic cancer. The reality is this: early stage disease treated with irradiation + Bavi, and/or early stage disease treated with chemo+irradiaton+ Bavi is sensible. Expecting Bavi to make a significant dent in metastatic pancreatic cancer (or lung cancer or breast cancer) is almost certainly not in the cards. Those who understand cancer will stay aboard. Those who are clueless will sell. Utilizing an exclusive "flipped" membrane phospholipid docking site still makes sense. Curing metastatic pancreatic cancer with an immunological stimulant does not.